Silexion Therapeutics Ltd. (SLXN) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
SLXN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Silexion Therapeutics Ltd. (SLXN) trades at a price-to-earnings ratio of -0.1x, with a stock price of $0.52 and trailing twelve-month earnings per share of $-3.81.
The current P/E is 103% below its 5-year average of 1.8x. Over the past five years, SLXN's P/E has ranged from a low of 0.3x to a high of 4.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SLXN trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SLXN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SLXN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SLXN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $74B | 17.1Lowest | 2.70Best | +8% | |
| $21B | 25.5 | 6.01 | +171%Best | |
| $176B | 26.8 | 12.67 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SLXN Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $1.92 | $5.53 | 0.3x | -80% |
| FY2025 Q3 | $3.40 | $6.75 | 0.5x | -72% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $12.15 | $2.72 | 4.5x | +152% |
Average P/E for displayed period: 1.8x
See SLXN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLXN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLXN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLXN — Frequently Asked Questions
Quick answers to the most common questions about buying SLXN stock.
Is SLXN stock overvalued or undervalued?
SLXN trades at -0.1x P/E, below its 5-year average of 1.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SLXN's valuation compare to peers?
Silexion Therapeutics Ltd. P/E of -0.1x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SLXN's PEG ratio?
SLXN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.